Aug. 17 at 3:19 PM
$SLS Does everyone realize - BAT for the REGAL Control ARM - Aza+VEN Failed 3 Large Phase 3 Trials conducted by
$ABBV
- BAT FAILED 3 AML Remission Maintenance Trials - FAILED
- MOS for BAT in First Remission was 17.3 Months / > 67.6 w GPS
It is NOT COMPLICATED
$100K Invested Here in SLS Shares today - Could EASILY BE - EASILY Be worth
$1M to
$2.5M in the NEXT Days when the Imminently Due Phase 3 Registrational Results are Announced ---
Registrational - ie A FDA Green light - to Generate Tens of Billions of Dollars in REAL Revenue worth Every nickel of
$50B to Big Pharma.
Do the MATH:
12,500 AML CR2/3 Patients Each Year /
$500K Lifetime Rev per patient
40,000 AML CR1 Patients Each Year
$740K Lifetime Rev Per Patient
300,000 AML Patients Currently in Remission /
$740K Rev Per patient
